For sponsors & CROs
An independent site with a practice network underneath it.
We run a freestanding research facility in Miami and we run studies inside the offices of the physicians who already treat the patients your protocol needs. One team executes both. The practical effect is that identification starts during startup rather than after activation — and that retention holds once it does.
Top global enroller
On a recent multinational vaccine study
98%
Overall participant retention
Same day
Contract turnaround, IRB submitted in parallel
Phase II–IV
Eight core therapeutic areas
The model
Why the hybrid matters to your timeline
Dedicated sites have the infrastructure but stall at recruitment. Community models recruit but execute inconsistently. We are built to do both, and the difference shows up in retention, not just first-patient-in.
Pipeline before launch
Our investigators’ own panels are the recruitment source, so identification starts during startup rather than after activation.
One accountable team
The same coordinators and the same lead run the study whether the visit happens at our facility or in a partner practice. Documentation does not vary by site.
PI-answered feasibility
Questionnaires are completed by the principal investigator personally, with enrollment commitments we intend to meet rather than numbers designed to win the award.
Bilingual by default
The entire team works in English and Spanish, including consent. In South Florida that is an enrollment and retention advantage, not a nicety.
In-house contracting
Contract review and IRB submission run in parallel and stay in-house, so there is no outside-counsel queue between award and activation.
GCP as the operating standard
ICH E6(R3) and ALCOA+ applied to source, eSource and monitoring — with internal QA running continuously, not only before a visit.
First patient in
By the time a site is activated, our screening list already exists. We prescreen against the protocol during start-up rather than after green light, so first-patient-in becomes a scheduling question instead of a recruiting one.
Straight answers
The eight questions that decide a site.
This is what sponsors actually weigh before they award one. Our answer to each, without the gloss — we would rather you had the specifics now than at the qualification visit.
＋ How fast can you actually activate?
Contract review is in-house, so turnaround is often same day rather than a week in someone’s queue. IRB submission runs simultaneously with contract and budget negotiation, and frequently ahead of it. In practice we move as fast as the sponsor and CRO can keep up — the limiting factor is rarely on our side.
＋ What have you actually enrolled?
We finished as a top global enroller on a recent multinational vaccine study. That is not luck. The moment we see a protocol we start identifying candidates against inclusion and exclusion criteria from our own database and our investigators’ panels, so pre-screening is underway before the site is green-lit and first-patient-in is not starting from a standstill.
＋ Where do your participants come from?
For most indications the majority come out of our investigators’ own patient panels — people already under their care for the condition being studied, who already trust the physician asking. That is the whole point of the hybrid. Vaccine studies are the exception; healthy-volunteer recruitment is a different animal and comes largely from the community.
＋ And when the panel isn’t enough?
We run our own recruitment rather than waiting on a central vendor: site-run digital advertising, community outreach across Miami-Dade, Homestead and Broward, a participant referral program, and a maintained database of people who asked to hear about future studies. We can walk you through the funnel on any study we have run.
＋ Do the participants stay?
Overall retention runs around 98%, and the reason is structural rather than heroic. The coordinator who consented a participant is the one they see at every visit, the team is bilingual so nothing gets lost, and for many participants the visit happens at the practice they were already driving to. Retention is where the hybrid earns its keep.
＋ What eDiary compliance should we expect?
88% across participants currently enrolled, measured this quarter. We treat diary compliance as a daily operational metric rather than something discovered at a monitoring visit. Coordinators review compliance between visits and contact participants before a gap turns into a protocol deviation.
＋ How present is the investigator?
Our investigators are across the street. Literally. That proximity means eligibility questions, clinical significance determinations and safety reviews happen the same day rather than by voicemail the next. Feasibility questionnaires are answered by the principal investigator personally, not delegated down and signed off.
＋ What happens to the data before we see it?
We audit ourselves first. Internal QA runs continuously against ICH E6(R3) and ALCOA+, and we review source before it reaches a monitor. The intent is that findings are ours to fix rather than yours to discover — which is also why query volume and resolution time tend to stay low.
How we work
From contract to close-out
Most studies are site-ready within 3–4 weeks of contract execution. Here is what happens in that time, and what happens after.
01
Feasibility
Questionnaires answered by the PI personally. Realistic enrollment commitments, not numbers designed to win the study.
02
Activation
Contract review and IRB submission run in parallel. Contracts stay in-house, so there is no outside counsel delay.
03
Recruitment
Pre-screening begins before the site is green-lit, then physician referrals, site-run advertising, community outreach and our own database carry it — with the partner network active before launch.
04
Execution
Dedicated staff and one accountable lead per study. PIs stay engaged in patient progress; internal QA runs continuously.
05
Close-out
Source-to-EDC verification, query resolution and final reporting to GCP standards. The team that started the study finishes it.
Therapeutic areas
Where we have experience
Thirty-four indications across our three investigators. The brighter tiles are where the bench runs deepest — more than one investigator, or several studies behind them. If yours is not listed, ask; we will tell you honestly whether we are a fit.
Cardiovascular
10
Acute myocardial infarction
Heart failure, preserved & mildly reduced EF
HeFH and ASCVD
Post-PCI and peripheral endovascular events
Atrial fibrillation
In-stent restenosis
Chronic limb-threatening ischemia
Infrapopliteal disease
Femoropopliteal lesions
Venous vascular closure
Metabolic & endocrine
3
Type 2 diabetes
Obesity
Postmenopausal osteoporosis
Respiratory
3
COPD, frequent exacerbators
Chronic cough
Asthma
Rheumatology & immunology
7
Rheumatoid arthritis
Systemic lupus erythematosus
Psoriatic arthritis
Lupus nephritis
Giant cell arteritis
Chronic spontaneous urticaria
JAK-inhibitor therapy selection
Vaccines & infectious disease
4
Influenza
Norovirus gastroenteritis
COVID-19
Zoster
Dermatology
3
Atopic dermatitis
Plaque psoriasis
Alopecia areata
Gastroenterology, neurology & women's health
4
Ulcerative colitis
Osteoarthritis of the knee
Migraine
Contraception
On site
Everything your protocol needs, in one building
3,000 square feet across from Baptist Hospital, laid out for trial execution rather than adapted from a clinic. A private consenting area, a monitor workspace that is not a borrowed desk, and a cold chain with battery-backed power behind it. If your protocol needs something not here, ask — we source more often than we decline.
12-lead ECG
Automatic ECG calculation
24-hour Holter monitoring
Cardiac stress testing
Echocardiogram
Coronary CT angiography
MRI, CT and PET
DEXA bone density
Spirometry to ATS-2019
FeNO
Forced oscillometry
−20°C and −80°C freezers
2–8°C refrigeration with backup
Ambient centrifuge with ice bath
Same-day dry-ice shipping
24-hour Traceable temperature monitoring
Battery backup power
Access-controlled IP storage
Private consenting area
Dedicated monitor workspace
EMR with patient-reported outcomes
GCP-compliant record storage
Documented continuity plan
On-site phlebotomy
Who walks through the door
The population we reach
Miami is not a recruitment strategy we adopted — it is the catchment. Our investigators practice in a community most US sites spend real money trying to reach, and the panel skews older, which is exactly where cardiovascular, metabolic, respiratory and vaccine protocols need to recruit.
92%
Hispanic or Latino
Across the participants in our research database
98%
Retention
Overall, across our randomized participants
88%
eDiary compliance
Currently enrolled participants, measured this quarter
Bilingual as standard, not on request
Consent, source documentation, coordinator conversations and participant materials run in English and Spanish. Nothing waits on a translation vendor, and nobody screens out because of the language the visit is conducted in.
Participants come from the practice
On most protocols the majority of our randomized participants come off our own investigators' panels rather than a purchased list. That is what holds the mix steady from study to study instead of swinging with whatever the ad spend happened to reach that month.
Why people stay
The same coordinators every visit, contact between visits, and a front desk where participants are known by name rather than by subject number. People call us between studies just to check in. Overall, almost every discontinuation we have had was a life event no site controls — a move, an illness, a death — rather than someone quietly drifting away.
Diversity you can report on
If your protocol carries representative-enrollment targets you have to document, the diversity here is not something we go looking for once the study opens. It is who the practice already sees, which means we help you meet those commitments rather than explain later why the numbers came in short.
Next step
Send us the synopsis. We answer fast, either way.
You will get a straight read quickly. If the population is there, we will tell you what we can realistically commit to. If this study is not right for us, we will tell you that just as fast rather than sit on it and waste your time — a quick no is worth more to you than a slow maybe.